Holz, MD, discussed the approval and benefits of the ustekinumab biosimilar, Yesintek, emphasizing its comparable efficacy and safety to Stelara, and potential for increased patient access due to ...

Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting ...

It is time for the agency to start thinking like an innovator, not an impediment to innovation. By modernizing and ...

Alvotech/Teva and Biocon Biologics advanced US biosimilar access with FDA interchangeability for ustekinumab biosimilars, Selarsdi and Yesafili, plus broad 2025 formulary coverage for Biocon’s ...

Number 5: The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key challenges, including a lack of data in CD and opportunities to improve ...

Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of ...

Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...

Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements ...